keyword
MENU ▼
Read by QxMD icon Read
search

Tace

keyword
https://www.readbyqxmd.com/read/29036035/the-treatment-path-in-hepatocellular-carcinoma
#1
Hashem B El-Serag, Andrew X Zhu, Matthew S Johnson
The treatment approach for hepatocellular carcinoma (HCC) depends on the stage and extent of disease, the severity of the underlying liver disease, and the overall performance status of the patient. Treatment consists of 4 main strategies: surgery (eg, resection and liver transplant), locoregional procedures (eg, ablation and transarterial embolization), systemic therapies, and best supportive care. For patients with early-stage tumors, surgical treatment or ablation can be curative. Patients with intermediate-stage disease can be candidates for embolization, administered as either transarterial chemoembolization (TACE) or transarterial radioembolization (TARE)...
August 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29034691/combined-transarterial-chemoembolization-and-radiofrequency-ablation-for-small-treatment-na%C3%A3-ve-hepatocellular-carcinoma-infeasible-for-ultrasound-guided-radiofrequency-ablation-long-term-outcomes
#2
Dongho Hyun, Sung Ki Cho, Sung Wook Shin, Kwang Bo Park, Sang Yub Lee, Hong Suk Park, Young Soo Do
Background Ultrasound (US)-guided radiofrequency ablation (RFA) for small hepatocellular carcinoma (HCC) is often infeasible due to unfavorable location and poor conspicuity. Those small HCCs can be treated with combined transarterial chemoembolization (TACE) and RFA. Purpose To evaluate long-term outcomes of combined TACE and RFA for small treatment-naïve HCC infeasible for US-guided RFA. Material and Methods Between February 2009 and January 2014, 69 patients with small (≤3 cm) HCC infeasible for US-guided RFA received TACE and subsequent RFA in one session as a first-line treatment...
January 1, 2017: Acta Radiologica
https://www.readbyqxmd.com/read/29032942/aspartate-aminotransferase-to-platelet-ratio-predicts-response-to-transarterial-chemoembolisation-and-prognosis-in-hepatocellular-carcinoma-patients
#3
T Tang, J-L Qiu, G-W Li, M-P Huang, Y Li, Y-J Li, S-Z Gu
AIM: To evaluate the value of the aspartate aminotransferase-to-platelet ratio index (APRI) for hepatocellular carcinoma (HCC) patients who underwent transarterial chemoembolisation (TACE). MATERIALS AND METHODS: A total of 315 patients were enrolled, who were randomly divided into the training cohort (n=158) and the validation cohort (n=157). The optimal cut-off value of the APRI was determined using the X-tile software in the training cohort, and was validated in the validation cohort...
October 12, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/29032738/long-term-survival-in-a-patient-with-low-level-inflammatory-markers-and-liver-metastasis-converted-resectable-by-tace
#4
Malkhaz Mizandari, Natela Paksashvili, Nino Kikodze, Tamta Azrumelashvili, Ia Pantsulaia, Koba Shanava, Nona Janikashvili, Tinatin Chikovani
Case report presents the successful treatment of unresectable liver metastasis in a patient with colon cancer. A 44-year-old male underwent right hemicolectomy followed by capecitabine for a moderately differentiated adenocarcinoma of the colon. 2 years later, a liver metastatic lesion was detected and had increased in size despite chemotherapy with capecitabine plus oxaliplatin (XELOX). Curative liver resection was conducted after conversion of unresectable tumor to resectable by transarterial chemoembolization followed by chemotherapy - irinotecan with fluorouracil and folinic acid (FOLFIRI)...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/29029548/antiangiogenic-agents-after-first-line-and-sorafenib-plus-chemoembolization-a-systematic-review
#5
REVIEW
Andrea Casadei Gardini, Daniele Santini, Giuseppe Aprile, Nicola Silvestris, Emanuele Felli, Francesco Giuseppe Foschi, Giorgio Ercolani, Giorgia Marisi, Martina Valgiusti, Alessandro Passardi, Marco Puzzoni, Marianna Silletta, Oronzo Brunetti, Giovanni Gerardo Cardellino, Giovanni Luca Frassineti, Mario Scartozzi
Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rational to combine them. Though the strategy of combining TACE and sorafenib has been increasingly used in patients with unresectable HCC but the current evidence is controversial and its clinical role has not been determined yet...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29029414/targeting-adam17-inhibits-human-colorectal-adenocarcinoma-progression-and-tumor-initiating-cell-frequency
#6
Joseph Dosch, Elizabeth Ziemke, Shanshan Wan, Kathryn Luker, Theodore Welling, Karin Hardiman, Eric Fearon, Suneetha Thomas, Matthew Flynn, Jonathan Rios-Doria, Robert Hollingsworth, Ronald Herbst, Elaine Hurt, Judith Sebolt-Leopold
ADAM17 (a disintegrin and metalloproteinase 17)/TACE (TNFα converting enzyme) has emerged as a potential therapeutic target in colorectal cancer (CRC) and other cancers, due in part to its role in regulating various tumor cell surface proteins and growth factors and cytokines in the tumor microenvironment. The emergence of MEDI3622, a highly potent and specific antibody-based ADAM17 inhibitor, has allowed testing of the concept that targeting ADAM17 may be an important new therapeutic approach for CRC patients...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29016627/cost-effectiveness-analysis-of-treatment-with-non-curative-or-palliative-intent-for-hepatocellular-carcinoma-in-the-real-world-setting
#7
Hla-Hla Thein, Yao Qiao, Ahmad Zaheen, Nathaniel Jembere, Gonzalo Sapisochin, Kelvin K W Chan, Eric M Yoshida, Craig C Earle
Hepatocellular carcinoma (HCC) presentation is heterogeneous necessitating a variety of therapeutic interventions with varying efficacies and associated prognoses. Poor prognostic patients often undergo non-curative palliative interventions including transarterial chemoembolization (TACE), sorafenib, chemotherapy, or purely supportive care. The decision to pursue one of many palliative interventions for HCC is complex and an economic evaluation comparing these interventions has not been done. This study evaluates the cost-effectiveness of non-curative palliative treatment strategies such as TACE alone or TACE+sorafenib, sorafenib alone, and non-sorafenib chemotherapy compared with no treatment or best supportive care (BSC) among patients diagnosed with HCC between 2007 and 2010 in a Canadian setting...
2017: PloS One
https://www.readbyqxmd.com/read/28993945/drug-eluting-bead-transarterial-chemoembolization-in-the-treatment-for-unresectable-soft-tissue-sarcoma-refractory-to-systemic-chemotherapy-a-preliminary-evaluation-of-efficacy-and-safety
#8
Jia-Yan Ni, Hong-Liang Sun, Yao-Ting Chen, Jiang-Hong Luo, Wei-Dong Wang, Xiong-Ying Jiang, Dong Chen, Lin-Feng Xu
PURPOSE: To preliminarily evaluate the clinical efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) for unresectable soft tissue sarcoma refractory to systemic chemotherapy. METHODS: Ten patients with refractory sarcoma who underwent DEB-TACE therapy between January 2015 and January 2017 were identified. Clinical information and radiological data were retrospectively collected to analyze tumor response, overall survival (OS), progression-free survival and adverse events (AEs)...
October 9, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28992881/cost-effectiveness-analysis-of-transcatheter-arterial-chemoembolization-with-or-without-sorafenib-for-the-treatment-of-unresectable-hepatocellular-carcinoma
#9
Rong-Ce Zhao, Jing Zhou, Yong-Gang Wei, Fei Liu, Ke-Fei Chen, Qiu Li, Bo Li
BACKGROUND: Transcatheter arterial chemoembolization (TACE) and TACE in combination with sorafenib (TACE-sorafenib) have shown a significant survival benefit for the treatment of unresectable hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource implications. The objective of this study was to estimate the relative cost-effectiveness of TACE against TACE-sorafenib for unresectable HCC using a decision analytic model. METHODS: A Markov cohort model was developed to compare TACE and TACE-sorafenib...
October 15, 2017: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/28989699/the-status-of-transarterial-chemoembolization-treatment-in-the-era-of-precision-oncology
#10
REVIEW
Valerie Fako, Xin Wei Wang
Transarterial chemoembolization (TACE) is the gold standard of therapy for patients with unresectable intermediate stage hepatocellular carcinoma (HCC), and is also commonly used as postresection adjuvant therapy in Asia. The delivery of TACE is highly variable from center to center, and clinical decision making for patients is based primarily on tumor staging guidelines, with very little focus on individualized tumor features. This review will discuss recent efforts for improving patient outcomes with TACE treatment through personalized medicine advances, including ongoing clinical trials investigating the combination of targeted therapy with TACE and the discovery of prognostic biomarkers for predicting TACE response...
April 2017: Hepatic Oncology
https://www.readbyqxmd.com/read/28988687/orantinib-versus-placebo-combined-with-transcatheter-arterial-chemoembolisation-in-patients-with-unresectable-hepatocellular-carcinoma-oriental-a-randomised-double-blind-placebo-controlled-multicentre-phase-3-study
#11
Masatoshi Kudo, Ann-Lii Cheng, Joong-Won Park, Jae Hyung Park, Po-Chin Liang, Hisashi Hidaka, Namiki Izumi, Jeong Heo, Youn Jae Lee, I-Shyan Sheen, Chang-Fang Chiu, Hitoshi Arioka, Satoshi Morita, Yasuaki Arai
BACKGROUND: Orantinib is an oral multi-kinase inhibitor. This study was done to evaluate the efficacy of orantinib combined with conventional transcatheter arterial chemoembolisation (cTACE) in patients with unresectable hepatocellular carcinoma. METHODS: This randomised, double-blind, placebo-controlled, phase 3 study was done at 75 sites in Japan, South Korea, and Taiwan. Patients with unresectable hepatocellular carcinoma, no extra-hepatic tumour spread, and Child-Pugh score of 6 or less were randomly assigned (1:1) by interactive web response system using a computer-generated sequence to receive orantinib or placebo, within 28 days of cTACE...
October 4, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28988686/anti-angiogenic-therapy-in-the-setting-of-tace-an-elusive-synergy
#12
Bruno C Odisio, Ahmed O Kaseb
No abstract text is available yet for this article.
October 4, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28985514/visceral-adipose-tissue-macrophage-targeted-tace-silencing-to-treat-obesity-induced-type-2-diabetes
#13
Seok-Beom Yong, Yoonsung Song, Yong-Hee Kim
Obesity is an increasingly prevalent global health problem. Due to its close relations with metabolic diseases and cancer, new therapeutic approaches for treating obesity and obesity-induced metabolic diseases are required. Visceral white adipose tissue (WAT) has been closely associated with obesity-induced inflammation and adipose tissue macrophages (ATMs) are responsible for obesity-induced inflammation by releasing inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6. TNF-α converting enzyme (TACE) is a transmembrane enzyme that induces the enzymatic cleavage and release of inflammatory cytokines...
December 2017: Biomaterials
https://www.readbyqxmd.com/read/28982886/parenchymal-liver-blood-volume-and-dynamic-volume-perfusion-ct-measurements-of-hepatocellular-carcinoma-in-patients-undergoing-transarterial-chemoembolization
#14
COMPARATIVE STUDY
Nils Rathmann, Kerim Kara, Johannes Budjan, Thomas Henzler, Arman Smakic, Stefan O Schoenberg, Steffen J Diehl
AIM: Prospective comparison of cone beam C-Arm CT based parenchymal liver blood volume (PLBV) and dynamic volume perfusion CT (dVPCT) measurements in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolisation (TACE) with drug-eluting beads (DEB). PATIENTS AND METHODS: In 16 patients, changes of PLBV and dVPCT measurements [arterial liver parenchyma (ALP); temporal maximum intensity projection (MIP); hepatic perfusion index (HPI); portal venous parenchyma] were correlated to one another and to the modified Response Evaluation Criteria in Solid Tumors (mRECIST)...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28980065/conservative-endovascular-management-of-retained-placenta-accreta-with-marked-vascularity-after-abortion-or-delivery
#15
Akihiro Takeda, Wataru Koike
OBJECTIVE: To report our experience on the value of transcatheter arterial embolization (TAE) or transcatheter arterial chemoembolization (TACE) for the uterus-preserving management of retained placenta accreta with marked vascularity after abortion or delivery. STUDY DESIGN: Thirty-eight consecutive women with retained placenta accreta were retrospectively analyzed over a 5-year period. When elevated levels of serum β-hCG (> 25 mIU/mL) were detected, TACE with dactinomycin was chosen for devascularization along with cytotoxic effects on active trophoblasts; in contrast, if the serum β-hCG level was low (≤ 25 mIU/mL), TAE was chosen...
October 4, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28977910/evaluation-of-hepatectomy-and-palliative-local-treatments-for-gastric-cancer-patients-with-liver-metastases-a-propensity-score-matching-analysis
#16
Jiyang Li, Kecheng Zhang, Yunhe Gao, Hongqing Xi, Jianxin Cui, Wenquan Liang, Aizhen Cai, Bo Wei, Lin Chen
BACKGROUND: The optimal treatments for gastric cancer with liver metastases (GCLM) remain controversial. This study aimed to evaluate the efficacy of hepatectomy, RFA and TACE as local treatments for GCLM. METHODS: From 2001 to 2015, 119 consecutive patients who received multidisciplinary treatments based on curative gastrectomy and local treatments (hepatectomy, RFA and TACE) for liver metastases were enrolled in this retrospective cohort study. Patients were divided into Group A (46, hepatectomy) and Group B (73, either or both RFA and TACE)...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28975561/liver-transarterial-embolizations-in-metastatic-neuroendocrine-tumors
#17
REVIEW
Louis de Mestier, Magaly Zappa, Olivia Hentic, Valérie Vilgrain, Philippe Ruszniewski
The management of patients with well-differentiated neuroendocrine tumors (NET) and non-resectable liver metastases is challenging. Liver-directed transarterial embolization (TAE), transarterial chemo-embolization (TACE) and selective internal radiation therapy (SIRT) have a place of choice among other treatment modalities. However, their utilization relies on a low level of proof, due to the lack of prospective data, the absence of comparative studies and considerable heterogeneity between local practices...
October 3, 2017: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/28974984/transarterial-infusion-of-epirubicin-and-cisplatin-combined-with-systemic-infusion-of-5-fluorouracil-versus-transarterial-chemoembolization-using-doxorubicin-for-unresectable-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-a-retrospective-analysis
#18
Sung Won Lee, Hae Lim Lee, Nam Ik Han, Jung Hyun Kwon, Soon Woo Nam, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
BACKGROUND: More than one-third of hepatocellular carcinoma (HCC) patients are diagnosed at advanced stage with portal vein tumor thrombosis (PVTT) or extrahepatic metastasis. However, the outcomes of current therapeutic approaches are unsatisfactory. As a novel therapeutic strategy for unresectable HCC with PVTT, we analyzed the outcomes of transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil (TAC-ECF) and compared its therapeutic effects and toxicity with transarterial chemoembolization (TACE) using doxorubicin (DOX)...
October 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28967229/t-cells-responding-to-trypanosoma-cruzi-detected-by-membrane-tnf-%C3%AE-and-cd154-in-chagasic-patients
#19
Juan G Ripoll, Nicolás A Giraldo, Natalia I Bolaños, Nubia Roa, Fernando Rosas, Adriana Cuéllar, Concepción J Puerta, John M González
INTRODUCTION: Chagas disease is a parasitic infection whose pathogenesis is related to parasite persistence and a dysfunctional cellular immune response. Variability in cytokine secretion among chronic Trypanosoma cruzi-infected patients might preclude the identification of the pool of antigen specific T cells. The goal of this study was to determine the fraction of T cells responding to T. cruzi antigen measured by the expression of membrane TNF-α and CD154. METHODS: A total of 21 chagasic patients, 11 healthy and 5 non-chagasic cardiomyopathy controls were analyzed...
October 1, 2017: Immunity, Inflammation and Disease
https://www.readbyqxmd.com/read/28965953/irhom2-deficiency-relieves-tnf-%C3%AE-associated-hepatic-dyslipidemia-in-long-term-pm2-5-exposed-mice
#20
Chen-Xu Ge, Yu-Ting Qin, De-Shuai Lou, Qiang Li, Yuan-Yuan Li, Zhong-Ming Wang, Wei-Wei Yang, Ming Wang, Nan Liu, Zhen Wang, Peng-Xing Zhang, Yan-Yang Tu, Jun Tan, Min-Xuan Xu
Accumulating researches reported that particulate matter (PM2.5) is a risk factor for developing various diseases, including metabolic syndrome. Recently, inactive rhomboid protein 2 (iRhom2) was considered as a necessary modulator for shedding of tumor necrosis factor-α (TNF-α) in immune cells. TNF-α, a major pro-inflammatory cytokine, was linked to various pathogenesis of diseases, including dyslipidemia. Here, wild type (WT) and iRhom2-knockout (iRhom2(-/-)) mice were used to investigate the effects of iRhom2 on PM2...
September 28, 2017: Biochemical and Biophysical Research Communications
keyword
keyword
8327
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"